Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine

Migraine Clinical Trial

Official title:

Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03398668
• Other study ID #: SP301
• Status: Completed
• Phase: N/A
• Start date: February 22, 2018
• Est. completion date: December 30, 2018

Study information

• Verified date: March 2019
• Source: Neurolief Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the clinical performance and safety of a self administered abortive treatment for migraine headache using combined occipital and supraorbital transcutaneous nerve stimulator (Neurolief device, Relievion™).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 55
• Est. completion date: December 30, 2018
• Est. primary completion date: December 30, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Males and females Ages of 18 to 65 years old.

2. History of episodic or chronic migraine with or without aura meeting the diagnostic criteria listed in ICHD (International Classification of Headache Disorders)-III beta (2013) section 1, migraine, with the exception of ''complicated migraine'' (i.e., hemiplegic migraine, basilar-type migraine, ophthalmoplegic migraine, migrainous infarction).

3. Capable to corporate with the study protocol and to sign an informed consent.

Exclusion Criteria:

1. Patients having received Botox treatment in the head region in the prior 4 months.

2. Patients having received supraorbital or occipital nerve blocks in the prior 4 months.

3. History of Medication Overuse Headache.

4. Patients using opioid medication.

5. Allodynia: intolerance to supraorbital and/or occipital neurostimulation that makes the treatment not applicable (the patients will be excluded if they are unable to tolerate the first 10 minutes of neurostimulation).

6. Implanted metal or electrical devices in the head (not including dental implants).

7. Patient having had a previous experience with the Relievion™ device.

8. Patients who have concomitant epilepsy.

9. History of neurosurgical interventions.

10. Patients with implanted neurostimulators, surgical clips (above the shoulder line) or any medical pumps.

11. History of drug abuse or alcoholism.

12. Participation in current clinical study or participated in a clinical study within 3 months prior to this study.

13. Skin lesion or inflammation at the region of the stimulating electrodes.

14. Personality or somatoform disorder.

15. Pregnancy or Lactation.

16. Women with child bearing potential without medically acceptable method of contraception.

17. History of cerebrovascular event.

18. Subjects with recent brain or facial trauma (occurred less than 3 months prior to this study).

19. Patients using Cannabis

20. Patients with head circumference smaller than 51 centimeters or head circumference larger than 60 centimeters.

Related Conditions & MeSH terms

• Migraine
• Migraine Disorders

Intervention

Device:
• Relievion device- Treatment stimulation
1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation
• Relievion Device- Sham stimulation
1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation

Locations

Country	Name	City	State
Israel	Laniado Medcial Center	Netanya

Sponsors (1)

Lead Sponsor	Collaborator
Neurolief Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Safety endpoints will consist of recording of adverse events and serious adverse events during the study. Device related adverse events will be evaluated between study groups	Safety endpoints will consist of recording of adverse events and serious adverse events during the study. Device related adverse events will be evaluated between study groups	1, 2, 24 hours
Primary	Mean change of pain score (measured on a visual analog scale=VAS) at 1 hour compared to baseline	visual analog scale (VAS) for pain score assessment: 11 point scale 0-no pain, 10-Intolerable pain	1 hour
Secondary	Mean change of pain score (measured by VAS) at 2 hours compared to baseline (if rescue therapy was not used).	visual analog scale (VAS) for pain score assessment: 11 point scale 0-no pain, 10-Intolerable painbaseline (if rescue therapy was not used).	2 hours
Secondary	Mean change of pain score (measured by VAS) at 24 hours compared to baseline (if rescue therapy was not used).	Mean change of pain score (measured by VAS) at 24 hours compared to baseline (if rescue therapy was not used).	24 hours
Secondary	Proportion of patients not having required rescue medication within 24 hours	Proportion of patients not having required rescue medication within 24 hours	24 hours
Secondary	Proportion of patients not having required rescue medication at 2 hours compared to baseline.	Proportion of patients not having required rescue medication at 2 hours	2 hours
Secondary	Proportion of patients pain free at 1,2 and 24 hours from baseline (if rescue therapy was not used).	Proportion of patients pain free at 1,2 and 24 hours from baseline (if rescue therapy was not used).	1, 2, 24 hours
Secondary	Proportion of "responders" ("responder" is defined as decrease of at least 50% in VAS pain score from baseline) at 1,2 and 24 hours from baseline (if rescue therapy was not used).	visual analog scale (VAS) for pain score assessment: 11 point scale 0-no pain, 10-Intolerable pain	1, 2, 24 hours